Literature DB >> 24715566

Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.

Hershel Raff1, Susmeeta T Sharma, Lynnette K Nieman.   

Abstract

The hypothalamic-pituitary-adrenal (HPA) axis is a classic neuroendocrine system. One of the best ways to understand the HPA axis is to appreciate its dynamics in the variety of diseases and syndromes that affect it. Excess glucocorticoid activity can be due to endogenous cortisol overproduction (spontaneous Cushing's syndrome) or exogenous glucocorticoid therapy (iatrogenic Cushing's syndrome). Endogenous Cushing's syndrome can be subdivided into ACTH-dependent and ACTH-independent, the latter of which is usually due to autonomous adrenal overproduction. The former can be due to a pituitary corticotroph tumor (usually benign) or ectopic ACTH production from tumors outside the pituitary; both of these tumor types overexpress the proopiomelanocortin gene. The converse of Cushing's syndrome is the lack of normal cortisol secretion and is usually due to adrenal destruction (primary adrenal insufficiency) or hypopituitarism (secondary adrenal insufficiency). Secondary adrenal insufficiency can also result from a rapid discontinuation of long-term, pharmacological glucocorticoid therapy because of HPA axis suppression and adrenal atrophy. Finally, mutations in the steroidogenic enzymes of the adrenal cortex can lead to congenital adrenal hyperplasia and an increase in precursor steroids, particularly androgens. When present in utero, this can lead to masculinization of a female fetus. An understanding of the dynamics of the HPA axis is necessary to master the diagnosis and differential diagnosis of pituitary-adrenal diseases. Furthermore, understanding the pathophysiology of the HPA axis gives great insight into its normal control.
© 2014 American Physiological Society.

Entities:  

Mesh:

Year:  2014        PMID: 24715566      PMCID: PMC4215264          DOI: 10.1002/cphy.c130035

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  270 in total

Review 1.  Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations.

Authors:  Hershel Raff
Journal:  Endocrine       Date:  2013-07-10       Impact factor: 3.633

2.  Hypogonadism and mineralocorticoid excess. The 17-hydroxylase deficiency syndrome.

Authors:  O Goldsmith; D H Solomon; R Horton
Journal:  N Engl J Med       Date:  1967-09-28       Impact factor: 91.245

3.  A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome.

Authors:  H Raff; J W Findling
Journal:  Clin Chem       Date:  1989-04       Impact factor: 8.327

Review 4.  Corticotropin-releasing hormone: clinical applications.

Authors:  L K Nieman; D L Loriaux
Journal:  Annu Rev Med       Date:  1989       Impact factor: 13.739

5.  Rapid as well as delayed inhibitory effects of glucocorticoid hormones on pituitary adrenocorticotropic hormone release are mediated by type II glucocorticoid receptors and require newly synthesized messenger ribonucleic acid as well as protein.

Authors:  G Dayanithi; F A Antoni
Journal:  Endocrinology       Date:  1989-07       Impact factor: 4.736

Review 6.  Cushing's Syndrome: important issues in diagnosis and management.

Authors:  James W Findling; Hershel Raff
Journal:  J Clin Endocrinol Metab       Date:  2006-07-25       Impact factor: 5.958

Review 7.  Syndromes of glucocorticoid resistance.

Authors:  G P Chrousos; S D Detera-Wadleigh; M Karl
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

8.  Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.

Authors:  Z E Belaya; L Y Rozhinskaya; G A Melnichenko; A G Solodovnikov; N V Dragunova; A V Iljin; L K Dzeranova; I I Dedov
Journal:  Osteoporos Int       Date:  2013-01-29       Impact factor: 4.507

9.  Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome.

Authors:  Elena Valassi; Brooke Swearingen; Hang Lee; Lisa B Nachtigall; Daniel A Donoho; Anne Klibanski; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2009-10-22       Impact factor: 5.958

10.  Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis.

Authors:  Ty Carroll; Hershel Raff; James W Findling
Journal:  Endocr Pract       Date:  2009 May-Jun       Impact factor: 3.443

View more
  30 in total

Review 1.  Estrogen Versus FSH Effects on Bone Metabolism: Evidence From Interventional Human Studies.

Authors:  Sundeep Khosla
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

2.  Trophoblast Retrieval and Isolation From the Cervix for Noninvasive, First Trimester, Fetal Gender Determination in a Carrier of Congenital Adrenal Hyperplasia.

Authors:  Alan D Bolnick; Rani Fritz; Chandni Jain; Leena Kadam; Jay M Bolnick; Brian A Kilburn; Manvinder Singh; Michael P Diamond; Sascha Drewlo; D Randall Armant
Journal:  Reprod Sci       Date:  2016-02-25       Impact factor: 3.060

3.  Acute stress response to a cognitive task in patients with major depressive disorder: potential metabolic and proinflammatory biomarkers.

Authors:  Tatiana Druzhkova; Ksenia Pochigaeva; Aleksander Yakovlev; Evdokia Kazimirova; Maria Grishkina; Aleksey Chepelev; Alla Guekht; Natalia Gulyaeva
Journal:  Metab Brain Dis       Date:  2018-12-18       Impact factor: 3.584

4.  Urine free cortisol in the diagnosis of Cushing's syndrome: is it worth doing and, if so, how?

Authors:  Hershel Raff; Richard J Auchus; James W Findling; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2014-11-25       Impact factor: 5.958

5.  Is the hypothalamic-pituitary-adrenal axis disrupted in type 2 diabetes mellitus?

Authors:  Hershel Raff; Steven B Magill
Journal:  Endocrine       Date:  2016-09-30       Impact factor: 3.633

6.  Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep.

Authors:  Clarissa Krekeler; Peter Kropp; Antje Katrin Blacha; Amir-Hossein Rahvar; Birgit Harbeck
Journal:  Endocrine       Date:  2021-02-24       Impact factor: 3.633

Review 7.  Cushing's syndrome: from physiological principles to diagnosis and clinical care.

Authors:  Hershel Raff; Ty Carroll
Journal:  J Physiol       Date:  2015-01-05       Impact factor: 5.182

8.  Accuracy of immunoassay and mass spectrometry urinary free cortisol in the diagnosis of Cushing's syndrome.

Authors:  G Aranda; M Careaga; F A Hanzu; I Patrascioiu; P Ríos; M Mora; B Morales-Romero; W Jiménez; I Halperin; G Casals
Journal:  Pituitary       Date:  2016-10       Impact factor: 4.107

9.  Brain Differences in the Prefrontal Cortex, Amygdala, and Hippocampus in Youth with Congenital Adrenal Hyperplasia.

Authors:  Megan M Herting; Anisa Azad; Robert Kim; J Michael Tyszka; Mitchell E Geffner; Mimi S Kim
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 10.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.